Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
ENLV 
Enlivex Therapeutics Ltd (ENLV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: ENLV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $10
1 Year Target Price $10
| 1 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -56.61% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 25.51M USD | Price to earnings Ratio - | 1Y Target Price 10 |
Price to earnings Ratio - | 1Y Target Price 10 | ||
Volume (30-day avg) 2 | Beta 0.9 | 52 Weeks Range 0.81 - 2.10 | Updated Date 11/1/2025 |
52 Weeks Range 0.81 - 2.10 | Updated Date 11/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.57 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.82% | Return on Equity (TTM) -55.02% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 6237546 | Price to Sales(TTM) - |
Enterprise Value 6237546 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -1.49 | Shares Outstanding 24292833 | Shares Floating 21390876 |
Shares Outstanding 24292833 | Shares Floating 21390876 | ||
Percent Insiders 4.53 | Percent Institutions 11.5 |
Upturn AI SWOT
Enlivex Therapeutics Ltd
Company Overview
History and Background
Enlivex Therapeutics Ltd. is a clinical-stage immunotherapy company dedicated to developing treatments for life-threatening inflammatory and immune conditions. Founded in 2005, it focuses on modulating the immune system to prevent and treat organ dysfunction and failure.
Core Business Areas
- Immune Modulation Therapies: Development of Allocetrau2122, a cell therapy aimed at rebalancing the immune system in severe inflammatory and immune conditions.
Leadership and Structure
Dr. Oren Hershkovitz is the CEO. The company has a board of directors overseeing its operations and strategic direction. The organizational structure includes departments for research and development, clinical trials, and corporate management.
Top Products and Market Share
Key Offerings
- Allocetrau2122: Allocetrau2122 is Enlivex's lead product candidate, designed to reprogram immune cells and resolve organ dysfunction. It is currently in clinical development for sepsis and other inflammatory conditions. Data on market share or revenue is not publicly available, as the product is not yet approved. Competitors include companies developing other immunomodulatory therapies and sepsis treatments, such as those targeting specific cytokines or immune checkpoints.
Market Dynamics
Industry Overview
The industry is characterized by increasing demand for innovative immunotherapies targeting severe inflammatory conditions, such as sepsis and cytokine release syndrome. There's significant unmet need and high potential market value for effective treatments.
Positioning
Enlivex is positioned as a pioneer in developing cell-based immunotherapy for immune rebalancing. Its competitive advantage lies in its novel approach to immune modulation using Allocetrau2122.
Total Addressable Market (TAM)
The TAM for sepsis and severe inflammatory conditions is substantial, estimated to be in the billions of dollars. Enlivex is positioned to capture a share of this market if Allocetrau2122 proves successful in clinical trials.
Upturn SWOT Analysis
Strengths
- Novel immunotherapy approach
- Promising preclinical and clinical data
- Experienced management team
- Strong intellectual property portfolio
Weaknesses
- Dependence on single product candidate (Allocetrau2122)
- High clinical trial risk
- Limited financial resources compared to larger pharmaceutical companies
- Not yet FDA approved
Opportunities
- Successful clinical trial results leading to regulatory approval
- Expansion of Allocetrau2122 to other inflammatory conditions
- Partnerships with larger pharmaceutical companies
- Growing demand for effective immunotherapies
Threats
- Clinical trial failures
- Competition from other immunotherapies
- Regulatory hurdles
- Changes in healthcare reimbursement policies
Competitors and Market Share
Key Competitors
- LLY
- BMY
- ABBV
Competitive Landscape
Enlivex is a smaller player compared to larger pharmaceutical companies in the immunotherapy space. Its competitive advantage lies in its novel approach to immune modulation.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by progress in clinical development and expansion of the company's pipeline.
Future Projections: Future growth depends on the success of Allocetrau2122 in clinical trials and potential regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Recent initiatives include advancing clinical trials for Allocetrau2122 in sepsis and other inflammatory conditions.
Summary
Enlivex Therapeutics is a clinical-stage immunotherapy company with a novel approach to treating inflammatory conditions. The company's future hinges on the success of its lead product candidate, Allocetrau2122, in clinical trials. While the potential market is substantial, Enlivex faces significant clinical and regulatory risks, along with competition from larger pharmaceutical companies. A successful FDA approval would significantly de-risk the company.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- ClinicalTrials.gov
- Analyst reports
Disclaimers:
This analysis is for informational purposes only and should not be considered investment advice. The information provided is based on publicly available data and may not be exhaustive or completely accurate. Investing in biotechnology companies carries significant risk.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Enlivex Therapeutics Ltd
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1995-12-12 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.enlivex.com |
Full time employees - | Website https://www.enlivex.com | ||
Enlivex Therapeutics Ltd., together with its subsidiaries, operates as a clinical-stage macrophage reprogramming immunotherapy company in Israel. Its product pipeline is the Allocetra (ENX-CL-02-002), which is in phase II clinical trial for the treatment of organ dysfunction and failure caused by sepsis; and Allocetra (ENX-CL-05-001), which is in phase I/II clinical trial to treat moderate knee osteoarthritis. The company also develops 0189-22-KMC, which is in phase I/II clinical trial to treat end-stage knee osteoarthritis; 0006-24-KMC, which is in phase I/II clinical trial for the treatment of Basal thumb osteoarthritis; and ENX-CL-06-001 to treat Psoriatic arthritis and is in phase I/II clinical trial. Enlivex Therapeutics Ltd. was founded in 2005 and is headquartered in Ness Ziona, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.